Physician profile
John E Panter
NPI 1407294655
$3,542.29
in general payments reported to CMS, 2019-2025
35 companies · $796 in 2025
The $796 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $218 · 2022: $610 · 2023: $704 · 2024: $1,215 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,714.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $936.16 | 2021-2025 | |
| Pfizer INC. | $419.91 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $227.49 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $218.64 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.57 | 2022-2025 | Jardiance |
| Lilly USA, LLC | $163.63 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $123.62 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Otsuka America Pharmaceutical, INC. | $112.98 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $111.50 | 2024-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $89.46 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $77.02 | 2021-2023 | Verquvo, Steglatro, Vaxelis |
| Exact Sciences Corporation | $69.24 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $66.74 | 2024 | Voquezna |
| Abbott Laboratories | $63.54 | 2022-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $61.39 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $61.00 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.67 | 2022-2025 | Xifaxan, Trulance |
| Lundbeck LLC | $45.85 | 2024-2025 | Rexulti |
| Inspire Medical Systems, INC. | $41.61 | 2025 | Inspire |
| Seqirus USA INC | $39.48 | 2025 | Flucelvax, Fluad |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.85 | 2023 | |
| Sanofi Pasteur INC. | $34.75 | 2024 | |
| Idorsia Pharmaceuticals US INC | $31.36 | 2023 | Quviviq |
| Amgen INC. | $30.50 | 2023-2024 | Repatha |
| Mylan Specialty L.P. | $30.22 | 2022-2024 | Yupelri |
| Baxter Healthcare | $29.91 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| E.R. Squibb & Sons, L.L.C. | $29.16 | 2021-2022 | |
| Nevro Corp. | $29.14 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $24.86 | 2025 | Neffy |
| Viatris Specialty LLC | $21.06 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $19.03 | 2025 | Gvoke Hypopen |
| Bioventus LLC | $15.64 | 2021 | |
| Axonics, INC. | $15.63 | 2022 | |
| Amarin Pharma, INC. | $14.74 | 2021 | |
| Angiodynamics, INC. | $13.94 | 2024 | Auryon Laser System 100-120 Vac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Panter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.